Lipocine Inc.
For the period ended Jun 30, 2025. Filed Aug 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 5, 2025
LPCN$1.72+9.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| ITEM 6. | EXHIBITS |
|---|
INDEX TO EXHIBITS
| Exhibit · Incorporation By Reference | |||||
|---|---|---|---|---|---|
| Number | Exhibit Description | Form | SEC File No. | Exhibit | Filing Date |
| 3.1 | Amended and Restated Certificate of Incorporation | 8-K | 333-178230 | 3.2 | 7/25/2013 |
| 3.2 | Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Lipocine Inc. | 8-K | 333-178230 | 3.4 | 6/28/2022 |
| 3.3 | Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Lipocine Inc. | 8-K | 333-178230 | 3.2 | 5/11/2023 |
| 3.4 | Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Lipocine Inc. | 8-K | 333-178230 | 3.4 | 6/4/2025 |
| 3.5 | Certificate of Designation of Series A Junior Participating Preferred Stock. | 8-K | 333-178230 | 3.1 | 12/1/2015 |
| 3.6 | Certificate of Increase of Series A Junior Participating Preferred Stock | 8-K | 333-178230 | 3.1 | 11/1/2021 |
| 3.7 | Certificate of Amendment to Certificate of Designation of Series A Junior Participating Preferred Stock. | 8-K | 333-178230 | 3.1 | 10/22/2024 |
| 3.8 | Certificate of Designation of Series B Preferred Stock | 8-K | 333-178230 | 3.2 | 3/10/2023 |
| 31.1* | Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | ||||
| 31.2* | Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | ||||
| 32.1** | Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. 1350 (1) | ||||
| 32.2** | Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. 1350 (1) | ||||
| 101.INS* | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | ||||
| 101.SCH* | Inline XBRL Taxonomy Extension Schema Document | ||||
| 101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document | ||||
| 101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document | ||||
| 101.LAB* | Inline XBRL Taxonomy Extension Labels Linkbase Document | ||||
| 101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document | ||||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | ||||
| * | Filed herewith | ||||
| ** | Furnished herewith | ||||
| (1) | This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act, or the Exchange Act (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Lipocine Inc. | |
| (Registrant) | |
| Dated: August 5, 2025 | /s/ Mahesh V. Patel |
|---|---|
| Mahesh V. Patel, President and Chief Executive Officer (Principal Executive Officer and Principal Financial Officer) | |
| Dated: August 5, 2025 | /s/ Krista Fogarty |
| Krista Fogarty, Corporate Controller (Principal Accounting Officer) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.